In multiple myeloma, CD47 expression was positively correlated with disease progression, while in ovarian carcinoma the low expression of CD47 in tumor cells not only reflected the patient's prognosis, but also predicted the patient's disease stage, and most importantly, the response to chemotherapy [12, 13]. This evidence concerns the gene CD47 and neoplasm.